Stock GPCR STRUCTURE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Structure Therapeutics Inc.

Equities

GPCR

US86366E1064

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
35.82 USD -7.32% Intraday chart for Structure Therapeutics Inc. -8.83% -12.12%
May. 09 Structure Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 09 Cantor Fitzgerald Initiates Structure Therapeutics at Overweight Rating With $65 Price Target MT

Business Summary

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.

Number of employees: 93

Managers

Managers TitleAgeSince
Raymond Stevens FOU
 Founder 60 19-01-31
Jun Yoon DFI
 Director of Finance/CFO 46 19-01-31
Ying Li Ma CTO
 Chief Tech/Sci/R&D Officer 50 22-07-31
Xi Chen Lin CTO
 Chief Tech/Sci/R&D Officer 50 19-06-30
Mark Bach CTO
 Chief Tech/Sci/R&D Officer 67 21-05-31
Lani Ibarra CTO
 Chief Tech/Sci/R&D Officer - -
Tony Peng LAW
 General Counsel - -
Karen S. Wright AUD
 Comptroller/Controller/Auditor 69 -

Members of the board

Members of the board TitleAgeSince
Sharon Tetlow BRD
 Director/Board Member 64 22-03-28
Ted Love BRD
 Director/Board Member 65 23-08-02
Eric Dobmeier BRD
 Director/Board Member 55 22-11-30
Daniel Welch CHM
 Chairman 66 22-01-18
Ramy Farid BRD
 Director/Board Member 59 19-03-31
Raymond Stevens FOU
 Founder 60 19-01-31
Jun Yoon DFI
 Director of Finance/CFO 46 19-01-31
Joanne Waldstreicher BRD
 Director/Board Member 63 22-11-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 2,161 0 0 76.06 %
Stock B 0 32,857 0 0
Stock C 1 139,794,124 106,321,015 ( 76.06 %) 0
Stock D 0 12,800 0 0
Stock E 0 19,200 0 0

Shareholders

NameEquities%Valuation
Wellington Management Co. LLP
9.383 %
4,372,326 9.383 % 170 M $
Fidelity Management & Research Co. LLC
8.583 %
3,999,682 8.583 % 156 M $
Driehaus Capital Management LLC
5.578 %
2,599,079 5.578 % 101 M $
Avoro Capital Advisor LLC
5.007 %
2,333,333 5.007 % 91 M $
Federated Equity Management Company of Pennsylvania
4.865 %
2,267,206 4.865 % 88 M $
TCG Crossover Management LLC
4.527 %
2,109,584 4.527 % 82 M $
Adage Capital Partners GP LLC
3.770 %
1,756,918 3.770 % 68 M $
T Rowe Price Associates, Inc. (13F Subfiler)
3.604 %
1,679,436 3.604 % 65 M $
Janus Henderson Investors US LLC
3.314 %
1,544,416 3.314 % 60 M $
T. Rowe Price Investment Management, Inc.
2.816 %
1,312,195 2.816 % 51 M $
NameEquities%Valuation
BVF Partners LP
3.701 %
5,173,941 3.701 % 67 M $
Qiming Venture Partners Ltd.
3.534 %
4,941,022 3.534 % 64 M $
Ramy Farid
2.923 %
4,085,495 2.923 % 53 M $
Chen-Ming Yu
2.474 %
3,458,242 2.474 % 45 M $
Raymond Stevens
1.882 %
2,630,250 1.882 % 34 M $
Jun Yoon
1.874 %
2,620,050 1.874 % 34 M $
Impresa Management LLC
0.4120 %
575,934 0.4120 % 7 M $
Daniel Welch
0.0883 %
123,508 0.0883 % 2 M $
Ying Li Ma
0.0263 %
36,729 0.0263 % 477 184 $
Mark Bach
0.003090 %
4,320 0.003090 % 56 126 $

Company contact information

Structure Therapeutics, Inc.

601 Gateway Boulevard Suite 900

94080, South San Francisco

+

http://www.structuretx.com
address Structure Therapeutics Inc.(GPCR)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
35.82 USD
Average target price
76.89 USD
Spread / Average Target
+114.65%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
STRUCTURE THERAPEUTICS INC. Stock Structure Therapeutics Inc.
-12.12% 1.67B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+3.91% 109B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.87% 105B
ARGENX SE Stock argenx SE
-0.26% 22.25B
BIONTECH SE Stock BioNTech SE
-13.14% 22.09B
GENMAB A/S Stock Genmab A/S
-8.05% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.36% 17.58B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.66% 16.85B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.75% 13.76B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.70% 12.46B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. GPCR Stock
  4. Company Structure Therapeutics Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW